Summary
1RV Chart
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. ( RYTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & CEO Jennifer Chien - Executive VP & Head of North America Yann Mazabraud - Executive VP & Head of International Hunter Smith - CFO & Treasurer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Philip Nadeau - TD Cowen, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Angela Qian Faisal Khurshid - Leerink Partners LLC, Research Division Erik Wong Julian Pino Evan Wang Georgia Ban Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Presentation Operator " David Connolly Head of Investor Relations & Corporate Communications " David Meeker Chairman, President & CEO " Jennifer Chien Executive VP & Head of North America " Yann Mazabraud Executive VP & Head of International " Hunter Smith CFO & Treasurer " Michael Ulz Morgan Stanley, Research Division " Morgan Stanley, Research Division Philip Nadeau TD Cowen, Research Division " TD Cowen, Research Division Derek Archila Wells Fargo Securities, LLC, Research Division " Wells Fargo Securities, LLC, Research Division Angela Qian " Canaccord Genuity, Research Division Faisal Khurshid Leerink Partners LLC, Research Division " Leerink Partners LLC, Research Division Erik Wong " Goldman Sachs, Research Division Julian Pino " Stifel, Nicolaus & Company, Incorporated, Research Division Evan Wang " Guggenheim Securities, LLC, Research Division Georgia Ban " Jefferies LLC, Research Division Raghuram Selvaraju H.C.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.73 per share a year ago.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals Inc. (1RV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Rhythm Pharmaceuticals Inc. ever had a stock split?
Rhythm Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | David P. Meeker CEO | XMUN Exchange | US76243J1051 ISIN |
| US Country | 283 Employees | - Last Dividend | - Last Split | 5 Oct 2017 IPO Date |
Overview
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company with a focus on rare neuroendocrine diseases. Founded in 2008 and based in Boston, Massachusetts, the company originally operated under the name Rhythm Metabolic, Inc. before rebranding to Rhythm Pharmaceuticals, Inc. in October 2015. Through its development of targeted treatments, Rhythm Pharmaceuticals aims to address unmet medical needs within the realm of obesity disorders and other related conditions. The company has entered into several licensing agreements to bolster its research, development, and commercialization efforts, collaborating with notable partners such as LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd.
Products and Services
- IMCIVREE (setmelanotide)
IMCIVREE (setmelanotide) stands as Rhythm Pharmaceuticals' lead product candidate, representing a significant advancement in the treatment of rare forms of obesity. This novel therapeutic targets the melanocortin-4 receptor (MC4R), a critical component in the regulation of hunger and body weight. Its development and testing focus on patients with gene-driven deficiencies linked to obesity, including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), leptin receptor (LEPR) deficiency obesity, and conditions such as Bardet-Biedl and Alström syndrome. Currently, IMCIVREE is undergoing Phase 3 clinical trials aimed at evaluating its efficacy in treating heterozygous deficiency obesities related to POMC or LEPR, steroid receptor coactivator 1 (SRC1) deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other disorders associated with the MC4R pathway.
Contact Information
